Type 2 diabetes mellitus: Clinical aspects of genetics, nutrigenetics, and pharmacogenetics


Cite item

Full Text

Abstract

The review gives modern knowledge of the genetics, pharmacogenetics and nutrigenetics of type 2 diabetes mellitus. The knowledge of genetic determinants can refine our understanding of the pathogenesis of this disease and introduce pharmacogenetic and nutrigenetic approaches to its effective therapy and prevention.

References

  1. Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J Diabetes. 2014;5(2):128-140.
  2. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010;1212:59-77.
  3. Basile KJ, Johnson ME, Xia Q, Grant SF. Genetic susceptibility to type 2 diabetes and obesity: follow-up of findings from genome-wide association studies. Int J Endocrinol. 2014;2014:769671.
  4. Church C, Moir L, McMurray F, Girard C, Banks GT, Teboul L, Wells S, Brüning JC, Nolan PM, Ashcroft FM, Cox RD. Overexpression of Fto leads to increased food intake and results in obesity. Nat Genet. 2010;42(12):1086-1092. doi: 10.1038/ng.713.
  5. Mitchell JA, Church TS, Rankinen Τ, Earnest CP, Sui X, Blair SN. FTO genotype and the weight loss benefits of moderate intensity exercise. Obesity (Silver Spring). 2010;18(3):641-643. doi: 10.1038/oby.2009.311.
  6. Şahın S, Rüstemoğlu A, Tekcan A, Taşliyurt T, Güven H, Yığıt S. Investigation of associations between obesity and LEP G2548A and LEPR 668A/G polymorphisms in a Turkish population. Dis Markers. 2013;35(6):673-677. doi: 10.1155/2013/216279.
  7. Prakash J, Mittal B, Awasthi S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity: association with insulin resistance. Indian J Clin Biochem. 2013;28(2): 158-163.
  8. Bedel A, Nègre-Salvayre A, Heeneman S, Grazide MH, Thiers JC, Salvayre R, Maupas-Schwalm F. E-cadherin/beta-catenin/ T-cell factor pathway is involved in smooth muscle cell proliferation elicited by oxidized low-density lipoprotein. Circ Res. 2008; 103(7):694-701. doi: 10.1161/circresaha.107.166405.
  9. Chu H, Wang M, Zhong D, Shi D, Ma L, Tong N, Zhang Z. AdipoQ polymorphisms are associated with type 2 diabetes mellitus: a meta-analysis study. Diabetes Metab Res Rev. 2013;29(7):532-545. doi: 10.1002/dmrr.2424.
  10. Ali O. Genetics of type 2 diabetes. World J Diabetes. 2013;4(4):114-123.
  11. Switonski M, Mankowska M, Salamon S. Family of melanocortin receptor (MCR) genes in mammals-mutations, polymorphisms and phenotypic effects. J Appl Genet. 2013;54(4):461-472. doi: 10.1007/s13353-013-0163-z.
  12. do Carmo JM, da Silva AA, Dubinion J, Sessums PO, Ebaady SH, Wang Z, Hall JE. Control of metabolic and cardiovascular function by the leptin-brain melanocortin pathway. IUBMB Life. 2013;65(8):692-698. doi: 10.1002/iub.1187.
  13. McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol (Lausanne). 2013;4:52. doi: 10.3389/fendo.2013.00052.
  14. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol CellBiol. 2008;9(5):367-377. doi: 10.1038/nrm2391.
  15. Feng RN, Zhao C, Sun CH, Li Y. Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS One. 2011;6(4):e18480. doi: 10.1371/journal.pone.0018480.
  16. Liu Z, Ding Y, Xiu L, Pan HY, Liang Y, Zhong SQ, Liu WW, Rao SQ, Kong DL. A Meta-Analysis of the Association between TNF-α –308G>A Polymorphism and Type 2 Diabetes Mellitus in Han Chinese Population. PLoS One. 2013;8(3):e59421. doi: 10.1371/journal.pone.0059421.
  17. Zhou Y, Park SY, Su J, Bailey K, Ottosson-Laakso E, Shcherbina L, Oskolkov N, Zhang E, Thevenin T, Fadista J, Bennet H, Vikman P, Wierup N, Fex M, Rung J, Wollheim C, Nobrega M, Renström E, Groop L, Hansson O. TCF7L2 is a master regulator of insulin production and processing. Hum Mol Genet. 2014;23(24): 6419-6431. doi: 10.1093/hmg/ddu359.
  18. Kirkpatrick CL, Marchetti P, Purrello F, Piro S, Bugliani M, Bosco D, de Koning EJP, Engelse MA, Kerr-Conte J, Pattou F, Wollheim CB. Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoSOne. 2010;5(6):e11053.
  19. Le Bacquer O, Kerr-Conte J, Gargani S, Delalleau N, Huyvaert M, Gmyr V, Froguel P, Neve B, Pattou F. TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals. Diabetologia. 2012;55(10):2677-2681. doi: 10.1007/s00125-012-2660-8.
  20. Kato N. Insights into the genetic basis of type 2 diabetes. J DiabetesInvestig. 2013;4(3):233-244. doi: 10.1111/jdi.12067.
  21. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev DiabetStud. 2012;9(1):6-22. doi: 10.1900/rds.2012.9.6.
  22. Shikata K, Makino H. Microinflammation in the pathogenesis of diabetic nephropathy. J Diabetes Investig. 2013;4(2):142-149.
  23. Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, Venkatesan R, Wang J, Chen H. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care. 2012;35(6):1388-1393. doi: 10.2337/dc11-2142.
  24. Tang ZH, Fang Z, Zhou L. Human genetics of diabetic vascular complications. J Genet. 2013;92(3):677-694.
  25. Paneni F, Volpe M, Lüscher TF, Cosentino F. SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes. 2013;62(6):1800-1807. doi: 10.2337/db12-1648.
  26. Brennan E, McEvoy C, Sadlier D, Godson C, Martin F. The genetics of diabetic nephropathy. Genes (Basel). 2013;4(4):596-619. doi: 10.3390/genes4040596.
  27. Yigit S, Karakus N, Inanir A. Association of MTHFR gene C677T mutation with diabetic peripheral neuropathy and diabetic retinopathy. Mol Vis. 2013;19:1626-1630.
  28. Lu B, Hu J, Wen J, Zhang Z, Zhou L, Li Y, Hu R. Determination of peripheral neuropathy prevalence and associated factors in Chinese subjects with diabetes and pre-diabetes — ShangHai Diabetic neuRopathy Epidemiology and Molecular Genetics Study (SH-DREAMS). PLoS One. 2013;8(4):e61053. doi: 10.1371/journal.pone.0061053.
  29. Kuo JZ, Wong TY, Rotter JI. Challenges in elucidating the genetics of diabetic retinopathy. JAMA Ophthalmol. 2014;132(1):96-107. doi: 10.1001/jamaophthalmol.2013.5024.
  30. Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M, Kivimäki M, Humphries SE. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ. 2010;340:b4838. doi: 10.1136/bmj.b4838.
  31. Huang C, Florez JC. Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med. 2011;3(11):76. doi: 10.1186/gm292.
  32. Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Lang CC, Palmer CN, Pearson ER. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin PharmacolTher. 2010;87(1):52-56. doi: 10.1038/clpt.2009.176.
  33. Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Cytochrome P450 2C9*2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin PharmacolTher. 2008;83(2):288-292.
  34. Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics. 2010;11(11):1517-1523. doi: 10.2217/pgs.10.121.
  35. Holstein A, Hahn M, Körner A, Stumvoll M, Kovacs P. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet. 2011;12:30. doi: 10.1186/1471-2350-12-30.
  36. Becker ML, Pearson ER, Tkáč I. Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol. 2013;2013:686315.
  37. Sun X, Yu W, Hu C. Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. Biomed Res Int. 2014;2014:926713.
  38. Semiz S, Dujic T, Causevic A. Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med (Zagreb). 2013;23(2):154-171.
  39. Todd JN, Florez JC. An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics. 2014;15(4):529-539. doi: 10.2217/pgs.14.21.
  40. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D, Florez JC; Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010;59(10):2672-2681. doi: 10.2337/db10-0543.
  41. Pearson ER. Pharmacogenetics in diabetes. Curr Diab Rep. 2009;9(2):172-181.
  42. Stage TB, Christensen MM, Feddersen S, Feddersen S, Beck-Nielsen H, Brøsen K. The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics. 2013;23(4):219-227. doi: 10.1097/fpc.0b013e32835f91fc.
  43. Wagner R, Staiger H, Ullrich S, Stefan N, Fritsche A, Häring HU. Untangling the interplay of genetic and metabolic influences on beta-cell function: Examples of potential therapeutic implications involving TCF7L2 and FFAR1. Mol Metab. 2014;3(3):261-267. doi: 10.1016/j.molmet.2014.01.001.
  44. ‘t Hart LM, Fritsche A, Nijpels G, van Leeuwen N, Donnelly LA, Dekker JM, Alssema M, Fadista J, Carlotti F, Gjesing AP, Palmer CN, van Haeften TW, Herzberg-Schäfer SA, Simonis-Bik AM, Houwing-Duistermaat JJ, Helmer Q, Deelen J, Guigas B, Hansen T, Machicao F, Willemsen G, Heine RJ, Kramer MH, Holst JJ, de Koning EJ, Häring HU, Pedersen O, Groop L, de Geus EJ, Slagboom PE, Boomsma DI, Eekhoff EM, Pearson ER, Diamant M. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes. 2013;62(9):3275-3281. doi: 10.2337/db13-0227.
  45. Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010;42(2):142-148.
  46. Joffe YT, Collins M, Goedecke JH. The relationship between dietary fatty acids and inflammatory genes on the obese phenotype and serum lipids. Nutrients. 2013;5(5):1672-1705. doi: 10.3390/nu5051672.
  47. Steemburgo T, Azevedo MJ, Gross JL, Milagro FI, Campión J, Martínez JA. The rs9939609 polymorphism in the FTO gene is associated with fat and fiber intakes in patients with type 2 diabetes. J Nutrigenet Nutrigenomics. 2013;6(2):97-106. doi: 10.1159/000350741.
  48. Phillips CM, Goumidi L, Bertrais S, et al. Dietary saturated fat, gender and genetic variation at the TCF7L2 locus predict the development of metabolic syndrome. J Nutr Biochem. 2012;23(3): 239-244. doi: 10.1016/j.jnutbio.2010.11.020.
  49. Ortega-Azorín C, Sorlí JV, Asensio EM, Coltell O, Martínez-González MÁ, Salas-Salvadó J, Covas MI, Arós F, Lapetra J, Serra-Majem L, Gómez-Gracia E, Fiol M, Sáez-Tormo G, Pintó X, Muñoz MA, Ros E, Ordovás JM, Estruch R, Corella D. Associations of the FTO rs9939609 and the MC4R rs17782313 polymorphisms with type 2 diabetes are modulated by diet, being higher when adherence to the Mediterranean diet pattern is low. Cardiovasc Diabetol. 2012;11:137. doi: 10.1186/1475-2840-11-137.
  50. Langenberg C, Sharp SJ, Franks PW, Scott RA, Deloukas P, Forouhi NG, Froguel P, Groop LC, Hansen T, Palla L, Pedersen O, Schulze MB, Tormo MJ, Wheeler E, Agnoli C, Arriola L, Barricarte A, Boeing H, Clarke GM, Clavel-Chapelon F, Duell EJ, Fagherazzi G, Kaaks R, Kerrison ND, Key TJ, Khaw KT, Kröger J, Lajous M, Morris AP, Navarro C, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR, Rolandsson O, Sacerdote C, Sánchez MJ, Slimani N, Spijkerman AM, Tumino R, van der A DL, van der Schouw YT, Barroso I, McCarthy MI34, Riboli E, Wareham NJ. Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study. PLoS Med. 2014;11(5):e1001647. doi: 10.1371/journal.pmed.1001647.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies